|
|
|
| Novel cellular therapies for hepatobiliary malignancies |
| Jing-Nan Xue a,b,#, Yan-Yu Wang a,# , Yun-Chao Wang a,#, Nan Zhang a, Long-Hao Zhang a,b, Zheng-Hui Lu c, Li-Jin Zhao b,#, Hai-Tao Zhao a,∗ |
a Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
b Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China
c Hepatobiliary and Pancreatic Surgery, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen 518000, China
∗Corresponding author.
E-mail address: zhaoht@punch.cn (H.-T. Zhao).
# Contributed equally. |
|
|
|
Abstract Background: The mortalities of hepatobiliary malignancies are high. With the failure of conventional chemotherapy and unsatisfactory outcome of molecular targeted drugs, immune-based therapy has become a new focus of research in hepatobiliary cancers treatment.
Data sources: We performed a PubMed search with relevant articles published up to May 2022 and the following keywords: cellular immunotherapy, hepatobiliary cancer, antigen receptor T cell therapy, and receptor-engineered T cell. Information of clinical trials was obtained from https://clinicaltrials.gov/ .
Results: Cell therapies for hepatobiliary malignancies are at early stage of development. The current review showed that cellular therapies are safe and feasible in patients. These findings provide an important platform for future lager scale clinical trials on immunotherapy in patients with hepatobiliary malignancies.
Conclusions: With the continuous advances of cellular immunotherapy, the combination of cellular im- munotherapy with surgery, chemotherapy and radiotherapy will be new therapeutic strategies for patients with hepatobiliary cancer.
|
|
|
|
|
|
|
|
|
2022, Vol. 21 
